Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Aravive stock
Learn how to easily invest in Aravive stock.
Aravive Inc is a biotechnology business based in the US. Aravive shares (ARAV) are listed on the NASDAQ and all prices are listed in US Dollars. Aravive employs 17 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Aravive
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ARAV – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Aravive stock price (NASDAQ: ARAV)Use our graph to track the performance of ARAV stocks over time.
Aravive shares at a glance
|Latest market close||$2.36|
|52-week range||$2.16 - $9.95|
|50-day moving average||$3.01|
|200-day moving average||$4.19|
|Wall St. target price||$22.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.60|
Buy Aravive shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Aravive stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aravive price performance over time
|1 week (2022-01-09)||N/A|
|1 month (2021-12-16)||-13.24%|
|3 months (2021-10-20)||-36.90%|
|6 months (2021-07-20)||-49.57%|
|1 year (2021-01-20)||-59.93%|
|2 years (2020-01-17)||-81.17%|
|3 years (2019-01-18)||3.72|
|5 years (2017-01-20)||15.05|
|Revenue TTM||$12.1 million|
|Gross profit TTM||$-11,935,000|
|Return on assets TTM||-28.11%|
|Return on equity TTM||-58.32%|
|Market capitalisation||$51.1 million|
TTM: trailing 12 months
Aravive share dividends
We're not expecting Aravive to pay a dividend over the next 12 months.
Have Aravive's shares ever split?
Aravive's shares were split on a 1:6 basis on 15 October 2018. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aravive shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Aravive shares which in turn could have impacted Aravive's share price.
Aravive share price volatility
Over the last 12 months, Aravive's shares have ranged in value from as little as $2.16 up to $9.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aravive's is 2.8373. This would suggest that Aravive's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aravive, Inc. , a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc.
Aravive in the news
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Frequently asked questionsWhat percentage of Aravive is owned by insiders or institutions?
Currently 37.51% of Aravive shares are held by insiders and 22.967% by institutions. How many people work for Aravive?
Latest data suggests 17 work at Aravive. When does the fiscal year end for Aravive?
Aravive's fiscal year ends in December. Where is Aravive based?
Aravive's address is: River Oaks Tower, Houston, TX, United States, 77098 What is Aravive's ISIN number?
Aravive's international securities identification number is: US03890D1081 What is Aravive's CUSIP number?
Aravive's Committee on Uniform Securities Identification Procedures number is: 03890D108
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
How to buy HeartCore Enterprises (HTCR) stock when it goes public
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
Ask an Expert